Literature DB >> 15948116

Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas.

Mary Ann Thompson1, Jennifer Stumph, Sarah E Henrickson, Andreas Rosenwald, Qifu Wang, Sandy Olson, Stephen J Brandt, Jeremy Roberts, Xueqiong Zhang, Yu Shyr, Marsha C Kinney.   

Abstract

Anaplastic large cell lymphoma (ALCL) is an aggressive large T- or null-cell lymphoma. Most ALCLs arising in children and young adults express a constitutively active receptor tyrosine kinase, anaplastic lymphoma kinase (ALK). Anaplastic large cell lymphomas lacking ALK are clinically heterogeneous and their pathogenesis is unknown. This study is the first complementary DNA (cDNA) microarray analysis using RNA extracted from tumor tissue (7 ALK+ ALCLs and 7 ALK- ALCLs) to identify genes differentially expressed or shared between the ALK+ and ALK- tumors. Unsupervised hierarchical clustering using the top 11 most statistically significant discriminator cDNAs correctly grouped all ALK+ and ALK- tumors. Hierarchical clustering analysis using the 44 cDNAs with the greatest differential expression between ALK+ and ALK- RNAs grouped 6 of 7 ALK+ ALCLs together and 1 ALK+ ALCL with the ALK- group. In general, ALK+ tumors overexpress genes encoding signal transduction molecules (SYK , LYN , CDC37) and underexpress transcription factor genes (including HOXC6 and HOX A3 ) compared with the ALK- group. Cyclin D3 was overexpressed in the ALK+ group and the cell cycle inhibitor p19INK4D was decreased in the ALK- group, suggesting different mechanisms of promoting G 1 /S transition. Both groups had similar proliferation rates. Genes highly expressed in both ALK- and ALK+ ALCLs included kinases (LCK, protein kinase C, vav2, and NKIAMRE) and antiapoptotic molecules, suggesting possible common pathogenetic mechanisms as well.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15948116     DOI: 10.1016/j.humpath.2005.03.004

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  32 in total

Review 1.  Primary esophageal CD30-positive ALK-positive anaplastic large cell lymphoma: a case report and literature review.

Authors:  Ning Wu; Liewen Pang; Zhiming Chen; Yiqing Wang; Qinyun Ma; Gang Chen; Ji Chen; Jiechun Huang
Journal:  J Gastrointest Cancer       Date:  2011-03

Review 2.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

3.  Unusual presentation of anaplastic large cell lymphoma with clinical course mimicking fever of unknown origin and sepsis: autopsy study of five cases.

Authors:  Marina B Mosunjac; J Bruce Sundstrom; Mario I Mosunjac
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

Review 4.  Targeting the oncogene and kinome chaperone CDC37.

Authors:  Phillip J Gray; Thomas Prince; Jinrong Cheng; Mary Ann Stevenson; Stuart K Calderwood
Journal:  Nat Rev Cancer       Date:  2008-05-30       Impact factor: 60.716

5.  MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.

Authors:  Cuiling Liu; Javeed Iqbal; Julie Teruya-Feldstein; Yulei Shen; Magdalena Julia Dabrowska; Karen Dybkaer; Megan S Lim; Roberto Piva; Antonella Barreca; Elisa Pellegrino; Elisa Spaccarotella; Cynthia M Lachel; Can Kucuk; Chun-Sun Jiang; Xiaozhou Hu; Sharathkumar Bhagavathi; Timothy C Greiner; Dennis D Weisenburger; Patricia Aoun; Sherrie L Perkins; Timothy W McKeithan; Giorgio Inghirami; Wing C Chan
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

6.  Reactivation of Syk gene by AZA suppresses metastasis but not proliferation of breast cancer cells.

Authors:  Tian-Song Xia; Jing-Ping Shi; Qiang Ding; Xiao-An Liu; Yi Zhao; Yue-Xian Liu; Jian-Guo Xia; Shui Wang; Yong-Bin Ding
Journal:  Med Oncol       Date:  2011-02-24       Impact factor: 3.064

7.  Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines.

Authors:  R A Wilcox; D X Sun; A Novak; A Dogan; S M Ansell; A L Feldman
Journal:  Leukemia       Date:  2009-09-24       Impact factor: 11.528

8.  Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.

Authors:  Javeed Iqbal; Dennis D Weisenburger; Timothy C Greiner; Julie M Vose; Timothy McKeithan; Can Kucuk; Huimin Geng; Karen Deffenbacher; Lynette Smith; Karen Dybkaer; Shigeo Nakamura; Masao Seto; Jan Delabie; Francoise Berger; Florence Loong; Wing Y Au; Young-Hyeh Ko; Ivy Sng; James Olen Armitage; Wing C Chan
Journal:  Blood       Date:  2009-11-18       Impact factor: 22.113

9.  CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.

Authors:  Bettina Bisig; Aurélien de Reyniès; Christophe Bonnet; Pierre Sujobert; David S Rickman; Teresa Marafioti; Georges Delsol; Laurence Lamant; Philippe Gaulard; Laurence de Leval
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

10.  Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes.

Authors:  Ryan A Metcalf; Shuchun Zhao; Matthew W Anderson; Zhi Shun Lu; Ilana Galperin; Robert J Marinelli; Athena M Cherry; Izidore S Lossos; Yasodha Natkunam
Journal:  Mod Pathol       Date:  2010-01-08       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.